Uso de tolvaptan na doença renal policística autossômica dominante: uma revisão sistemática
DOI:
https://doi.org/10.34119/bjhrv7n2-123Keywords:
doença renal policística autossômica dominante, Tolvaptan, progressão de doença renal crônica, insuficiência renal crônicaAbstract
A doença renal policística autossômica dominante (DRPAD) é uma causa frequente de doença renal em estágio terminal em adultos. Formas mais graves são secundárias principalmente à mutação de genes que codificam a policistina 1 (PKD1) ocasionando múltiplos cistos que destroem o parênquima renal normal, culminando na insuficiência renal terminal – o pior desfecho da doença. No momento não existe tratamento definitivo para tal condição. Sendo preconizadas medidas do tratamento conservador da doença renal crônica como dieta, uso de bloqueadores de enzima conversora ou do receptor da angiotensina e hidratação. O Tolvaptan por ter efeito no mecanismo fisiopatológico da formação dos cistos pode ser um medicamento promissor. Uma Revisão Sistemática foi realizada para analisar evidências do impacto do Tolvaptan no tratamento da DRPAD e construir um guia prático de seu uso. A busca dos estudos foi realizada nos seguintes bancos de dados: Medline (Medical Analysis and Retrieval System Online), UpToDate, PubMed e Lilacs. Foram selecionados artigos de acordo com sua importância para a revisão. A busca nas bases de dados e análise de título/resumo levou a seleção de 100 artigos. Destes, 37 foram incluídos, uma vez que eles forneceram os dados consistentes para a síntese da revisão. A partir da revisão se evidenciou que o Tolvaptan é uma opção para terapia medicamentosa em pacientes com DRPAD e os estudos selecionados permitiram construir um guia prático de uso.
References
Rosseti S, Chauveau D, Walker D, Sagar-Malik A, Winearls CG, Torres VE, Harris PC. A complete mutation screen of the ADPKD genes by DHPLC. Kidney Int. 2002; 61 (5): 1588-99.
Torres VE, Higashihara E, Devuyst O, Chapman AB, Gasenvoort RT, Grantham JJ, et al. Effect of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease by CKD Stage: Results from the TEMPO 3:4 Trial. Clin J Am Soc Nephrol. 2016 may 11(5): 803–11.
Saini AK, Saini, R.; Singh S. Autosomal dominant polycystic kidney disease and pioglitazone for its therapy: a comprehensive review with an emphasis on the molecular pathogenesis and pharmacological aspects. Molecular Medicine 2020 dec 26 (128): 1-17.
Torres V E, Harris P C. Autosomal dominant polycystic kidney disease: the last 3 years. Kidney Int. 2009; jul 76 (2): 149–68.
Cornec-Le Gall E, Audrézet Marie-Pierre, Rousseau A, Hourmant M, Renaudineau E, Charasse C et al. The PROPKD Score A New Algorithm to Predict Renal Survival in Autosomal Dominant Polycystic Kidney Disease. J Am Soc Nephrol. 2016 mar 27(3): 942-51.
Shoaf SE, Ouyang J, Sergeyeya O, Estilo A, Li H, Leung Deborah. A Post Hoc Analysis of Statin Use in Tolvaptan Autosomal Dominant Polycystic Kidney Disease Pivotal Trials. Clin J Am Soc Nephrol. 2020 apr 15 (5): 643–50.
Chebib FT, Perrone RD, Chapman AB, Dahl NK, Harris PC, Mrug M, et al. A Practical Guide for Treatment of Rapidly Progressive ADPKD with Tolvaptan. J Am Soc Nephrol. 2018 sep; 29 (10): 2458–70.
Pamplona I.A, Garcia ML, Macias RPB, Micas DS, Ronsano JBM. Case report: tolvaptan-associated creatine kinase elevation in two patients with autosomal dominant polycystic kidney disease (ADPKD). Eur J Clin Pharmacol. 2020 8 jun; 76 (10): 1473–75.
Sommerer C, Zeier M. Clinical Manifestation and Management of ADPKD in Western Countries. Kidney Dis. 2016; 2 (3): 120–27.
Tetsa F, Magistroni R. ADPKD current management and ongoing trials. J Nephrol. 2020; 1 apr 33 (2): 223–37.
Gansevoort RT, Meijer E, Chapman AB, Czerwiec FS, Devuyst O, Grantham JJ, et al. Albuminuria and tolvaptan in autosomal-dominant polycystic kidney disease: results of the TEMPO 3:4 Trial. Nephrol Dial Transplant. 2015; dec 31 (11): 1887– 94.
Rastogi A, Ameen KM, Al-Baghdadi, Shaffer K, Nobakht N, Kambar M, et al. Autosomal dominant polycystic kidney disease: updated perspectives. Ther Clin Risk Manag. 2019; aug 15: 1041–52.
Bennett H, McEwan P, Hamilton K, O’Reilly K. Modelling the long-term benefits of tolvaptan therapy on renal function decline in autosomal dominant polycystic kidney disease: an exploratory analysis using the ADPKD outcomes model. BMC Nephrology. 2019; apr 20 (136): 1-9.
Watkins PB, Lewis HJ, Kaplowitz N, Alpers DH, Blais JD, Smotzer DM, et al. Clinical Pattern of Tolvaptan-Associated Liver Injury in Subjects with Autosomal Dominant Polycystic Kidney Disease: Analysis of Clinical Trials Database. Drug Safety. 2015; jul 38 (11): 1103–13.
Kramers BJ, Gastel MDAV, Boertien WE, Meijer E, Gansevoort RT. Determinants of Urine Volume in ADPKD Patients Using the Vasopressin V2 Receptor Antagonist Tolvaptan. Am J Kidney Dis. 2019; mar 73 (3): 354–62.
Muto S, Okada T, Shibasaki Y, Ibuki T, Horie S. Effect of tolvaptan in Japanese patients with autosomal dominant polycystic kidney disease: a post hoc analysis of TEMPO 3:4 and TEMPO Extension Japan. Clin Exp Nephrol. 2021; jun 25 (9): 1003–10.
Moriyama T, Nakayama Y, Soejima M, Yokata Y, Ota K, Ito Sakuya, et al. Effect of tolvaptan on renal involvement in patients with autosomal dominant polycystic kidney disease according to different gene mutations. Clin Exp Nephrol. 2020; nov 25 (3): 251–60.
Al Therwani S, Malmberg MES, Rosenbaek JB, Bech JN, Pedersen EB. Effect of tolvaptan on renal handling of water and sodium, GFR and central hemodynamics in autosomal dominant polycystic kidney disease during inhibition of the nitric oxide system: a randomized, placebo-controlled, double blind, crossover study. BMC Nephrology. 2017 aug 18 (268): 1, 15.
Barnawi RA, Attar RZ, Alfaer SS, Safdar OY. Is the light at the end of the tunnel nigh? A review of ADPKD focusing on the burden of disease and tolvaptan as a new treatment. Int J Nephrol Renovasc Dis. 2018; feb 11 :53–67.
Heida JE, Gasenvoort RT, Torres VE, Devuyst O, Perrone RD, Lee J, et al. The Effect of Tolvaptan on BP in Polycystic Kidney Disease: A Post Hoc Analysis of the TEMPO 3:4 Trial. J Am Soc Nephrol. 2021; apr 32 (7): 1801–12.
Torres V E, Chapman A B, Gansevoort RT, Perrone RD, Lee J, Hoke ME et al. Multicenter Study of Long-Term Safety of Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease. Clin J Am Soc Nephrol. 2020; dec 16 (1): 48–58.
Mochizuki T, Muto S, Miyake M, Tanaka T, Wang W. Safety and efficacy of Tolvaptan in real-world patients with autosomal dominant polycystic kidney disease- interim results of SLOW-PKD surveillance. Clin Exp Nephrol. 2021; jul 25 (11): 1231–39.
Yamaguchi T, Higashihara E, Okegawa T, Miyazaki I, Nutahara K. Optimal equation for estimation of glomerular filtration rate in autosomal dominant polycystic kidney disease: influence of tolvaptan. Clin Exp Nephrol, 2018; may 22 (5): 1213–23.
Horie S, Muto S, Kawano H, Okada T, Shabasaki Y, Nakajima K et al. Preservation of kidney function irrelevant of total kidney volume growth rate with tolvaptan treatment in patients with autosomal dominant polycystic kidney disease. Clin Exp Nephrol. 2021; jan 25 (5): 467–78.
Aiello V, Fusaroli M, Raschi E, Palazzini M, Hu L, Barbuto S et al. Pulmonary Embolism in a Patient with ADPKD Treated with Tolvaptan: From the Clinical Experience to the Analysis of the Food and Drug Administration Adverse Event Reporting System Registry. Kidney Int Rep. 2021; sep 6 (9): 2472–77.
Torres V E.; Meijer E.; Bae K. T.; Chapman A. B.; Devuyst O.; Gasenvoort R.T. et al. Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study. Am J Kidney Dis. 2011 1 may 57 (5): 692–99.
Boertien W E, Meijer E, de Jong PE, ter Horst GJ, Renken RJ, van der Jagt EJ et al. Short-term Effects of Tolvaptan in Individuals with Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney Function. Am J Kidney Dis. 2015 jun 65 (6): 833–41.
Irazabal MV, Torres VE, Hogan MC, Glockner J, King BF, Ofstie TG et. al. Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease. Kidney Int. 2011 aug 80 (3): 295–301.
Boertien WE, Meijer E, de Jong PE, Bakker SJL, Czerwiec FS. Short-term renal hemodynamic effects of tolvaptan in subjects with autosomal dominant polycystic kidney disease at various stages of chronic kidney disease. Kidney Int. 2013 dec 84 (6): 1278–86.
Muto S, Kawano H, Higashihara E, Narita I, Ubara Y, Matsuzaki T et. al. The effect of tolvaptan on autosomal dominant polycystic kidney disease patients: a subgroup analysis of the Japanese patient subset from TEMPO 3:4 trial. Clin Exp Nephrol. 2015 feb 19 (5): 867–77.
Tamma G, Mise AD, Ranieri M, Geller A, Tamma R, Zallone A et. al. The V2 receptor antagonist tolvaptan raises cytosolic calcium and prevents AQP2 trafficking and function: an in vitro and in vivo assessment. J Cell Mol Med. 2017 mar 21 (9): 1767–80.
Baur BP, Meaney CJ. Review of Tolvaptan for Autosomal Dominant Polycystic Kidney Disease. Pharmacotherapy. 2014 jun 34 (6): 605–16.
Fujiki T, Ando F, Murakami K, Isobe K, Mori T, Susa K et. al. Tolvaptan activates the Nrf2/HO-1 antioxidant pathway through PERK phosphorylation. Scientific Reports. 2019 jun. 9 (9245): 1-10.
Higashihara E, Torres VE, Chapman AB, Grantham JJ, Bae K, Watnick TJ et. al Tolvaptan in Autosomal Dominant Polycystic Kidney Disease: Three Years’ Experience. Clin J Am Soc Nephrol. 2011 sep 6 (10): 2499–507.
Oguro M, Kogure Y, Hoshino J, Ubara Y, Mizuno H, Sekine A et. al. Tolvaptan in Japanese patients with later-stage autosomal dominant polycystic kidney disease. J Nephrol. 2018 oct 31(6): 961–66.
Torres VE, Chapman AB, Devuyst O, Ganservoort RT, Perrone RD, Koch G et. al. Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease. N Engl J Med. 2017 nov 377 (20): 1930–42.
Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E et. al. Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease. N Engl J Med. 2012 dec 367 (25): 2407–18.
Liu F, Feng C, Shen H, Fu H, Mao J. Tolvaptan in Pediatric Autosomal Dominant Polycystic Kidney Disease: From Here to Where? Kidney Dis. 2021 sep 7 (5): 343-49.
Sans-Atxer L, Joly D. Tolvaptan in the treatment of autosomal dominant polycystic kidney disease: patient selection and special considerations. Int J Nephrol Renovasc Dis. 2018 jan 31 (11): 41–51.
Makabe S, Manabe S, Kataoka H, Akihisa T, Yoshida R, Ushio Y et. al. Urinary Aquaporin 2 as a Potential Indicator Predicting Tolvaptan Response in Patients With ADPKD. Kidney Int Rep. 2021 sep 6 (9): 2436–44.
Irazabal MV , Rangel LJ , Bergstralh EJ , Osborn SL , Harmon AJ , Sundsbak JL et al. Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials. J Am Soc Nephrol. 2015 jan 26(1): 160–72.
